Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Research Aimed at Improving Both Mood and Weight [NA]
This Clinical Trial Update reports completion of a study investigating an intervention to improve mood and weight in individuals with depres…
-
FDA approval · 2020-06-10FDA Approved: FLUOXETINE — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's generic fluoxetine through an Original Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome [Phase 1, Phase 2]
A completed Phase 1/2 trial studying a combination of Bifidobacterium longum 35624 and 1714 strains in adults with irritable bowel syndrome,…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder [Phase 4]
Phase 4 clinical trial investigating combinatorial pharmacogenomics testing in treatment-naïve major depressive disorder; the study status i…
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI [NA]
Clinical trial update for a multifamily group intervention aimed at reducing marital conflict and disability in veterans with mild traumatic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: Single Session of tACS in a Depressive Episode [NA]
A completed clinical trial evaluating a single session of transcranial alternating current stimulation (tACS) in a depressive episode for de…
-
CLINICAL_TRIALS trial_result · 2020-05-22Clinical Trial Update: The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive [Phase 2]
Phase 2 clinical trial assessing the effects of JNJ-39393406 on psychometric performance and residual depressive symptoms completed.
-
FDA approval · 2020-05-19FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Oxford Pharmaceuticals, LLC)
FDA approved a supplemental application for trazodone hydrochloride from Oxford Pharmaceuticals, LLC under an ANDA.
-
CLINICAL_TRIALS trial_result · 2020-05-14Clinical Trial Update: INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study [NA]
A completed study evaluating integration of depression treatment with diabetes care (INDEPENDENT) with posted results.
-
CLINICAL_TRIALS trial_result · 2020-05-14Clinical Trial Update: Effect Evaluation of Individual Placement and Support (IPS) [NA]
Clinical trial update reporting completion and results posting for an IPS-based evaluation in psychosis and substance abuse populations.
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: Comparison of Anyu Peibo With Placebo in Treatment of MDD in China [Phase 3]
Phase 3 clinical trial comparing Anyu Peibo with placebo in treatment of Major Depressive Disorder in China.
-
CLINICAL_TRIALS trial_result · 2020-04-30Clinical Trial Update: Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder [Phase 4]
Phase 4 trial update evaluating Pharmacogenomic Decision Support with GeneSight Psychotropic to guide treatment of major depressive disorder…
-
FDA approval · 2020-04-29FDA Approved: REMERONSOLTAB — Supplemental Application (Organon LLC)
FDA approved a supplemental application for REMERONSOLTAB (mirtazapine) submitted by Organon LLC.
-
FDA approval · 2020-04-29FDA Approved: REMERON — Supplemental Application (Organon LLC)
FDA approved a supplemental application for REMERON (mirtazapine) from Organon LLC. The approval updates the labeling to reflect the approve…
-
FDA approval · 2020-04-28FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
The FDA approved a supplemental application for Prozac (fluoxetine hydrochloride) submitted by Dista Products Company.
-
CLINICAL_TRIALS trial_result · 2020-04-28Clinical Trial Update: Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression [Phase 2]
Phase 2 study evaluating inhaled esketamine for treatment-resistant depression completed, reporting efficacy, safety, and pharmacokinetics.
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Clinical Study of Generic and Brand Bupropion in Depression [Phase 4]
Phase 4 trial comparing generic and brand bupropion in major depressive disorder completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-04-21Clinical Trial Update: Study of Naltrexone-Induced Blockade of Antidepressant Effects [Phase 4]
Phase 4 trial investigating naltrexone-induced blockade of antidepressant effects in major depressive disorder; study completed with results…
-
FDA approval · 2020-04-20FDA Approved: CYMBALTA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Cymbalta (duloxetine hydrochloride) from Eli Lilly, granting updated labeling under the NDA.
-
FDA approval · 2020-04-20FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for trazodone hydrochloride by Zydus Lifesciences Limited.
-
FDA approval · 2020-04-20FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Apotex Corp)
FDA approves a supplemental application for trazodone hydrochloride from Apotex Corp, authorizing a generic version of the antidepressant. T…
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD) [Phase 4]
A Phase 4 clinical trial evaluating intranasal ketamine with repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant maj…
-
CLINICAL_TRIALS trial_result · 2020-04-17Clinical Trial Update: Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) [Phase 4]
A Phase 4 relapse prevention study of vortioxetine (5, 10, 20 mg) in adults with major depressive disorder has completed, with results poste…
-
CLINICAL_TRIALS trial_result · 2020-04-16Clinical Trial Update: Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome [Phase 4]
Phase 4 trial update evaluating functional change and efficacy of duloxetine in patients with co-morbid major depressive disorder and soft t…
-
CLINICAL_TRIALS trial_result · 2020-04-16Clinical Trial Update: Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression [Phase 2, Phase 3]
Phase 2 and Phase 3 trial update evaluating the effects of antidepressant therapy on brain dopamine transporter activity in people with majo…